Drugs / TBC-3B
last change Jul 1999 re-read 2 minutes ago

TBC-3B

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 3 · a red edge is where a trial was stopped

19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT00056745 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000767 ? → Jul 1996 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase not applicable1 trial
NCT00000866 ? → Jul 1999 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as TBC-3B ClinicalTrials.gov intervention name — accepted as the source's own label NCT00056745
2

NCT00000767

NCT00000866

Modality Vaccine “HIV-1 candidate vaccine (TBC-3B)” NCT00000767
Route Other “by scarification” NCT00000866